Key Insights

The United Kingdom Continuous Glucose Monitoring (CGM) market is experiencing robust growth, driven by increasing prevalence of diabetes, technological advancements leading to improved accuracy and ease of use, and a rising preference for self-management among patients. The market, while currently smaller than some of its global counterparts, benefits from a strong healthcare infrastructure and a growing awareness of the benefits of CGM in preventing severe hypoglycemic events and improving overall diabetes management. While the precise market size for the UK in 2025 is unavailable, estimations based on global market growth rates and the UK's significant diabetic population suggest a market value in the tens of millions of pounds. The 15.90% CAGR projected globally indicates strong potential for similar or even higher growth in the UK, fuelled by the expanding adoption of advanced sensor technologies and increasing reimbursement coverage by the National Health Service (NHS). The market segments for sensors and durable devices are expected to maintain a balanced growth trajectory, with a predicted increase in demand for advanced, minimally invasive sensors. Key players like Abbott Diabetes Care, Dexcom, and Medtronic are expected to maintain market leadership through continuous innovation and strategic partnerships with healthcare providers. However, competition from newer entrants and challenges associated with pricing and reimbursement policies will shape future market dynamics.

Further growth will hinge on several factors, including the increased accessibility of CGM technologies to a broader patient base, enhanced integration with other diabetes management devices, and ongoing efforts to educate healthcare professionals and patients on the advantages of CGM. Challenges include the high cost of CGM systems, potentially limiting access for some patients, and the need for continuous technological advancements to overcome limitations such as accuracy and sensor lifespan. Despite these challenges, the long-term outlook for the UK CGM market remains positive, driven by increasing awareness of diabetes, technological innovation, and supportive government policies aimed at improving diabetes care. The growing focus on personalized medicine and remote patient monitoring also contributes to the market's potential for expansion.

United Kingdom Continuous Glucose Monitoring (CGM) Market Report: 2019-2033

This comprehensive report provides a detailed analysis of the United Kingdom Continuous Glucose Monitoring (CGM) market, covering the period 2019-2033. It offers invaluable insights into market structure, competitive dynamics, industry trends, and future growth prospects, making it an essential resource for industry stakeholders, investors, and researchers. The report includes detailed segmentation by component (Sensors, Durables), a thorough competitive landscape analysis, and key developments impacting market growth. With a base year of 2025 and a forecast period of 2025-2033, this report provides a robust foundation for strategic decision-making. The market value is presented in Millions.

United Kingdom Continuous Glucose Monitoring Market Market Structure & Competitive Dynamics

The UK CGM market exhibits a moderately concentrated structure, with key players like Abbott Diabetes Care, Dexcom Inc, Medtronic PLC, and Ascensia Diabetes Care holding significant market share. However, the presence of several smaller players and emerging companies fosters a dynamic competitive landscape. Innovation plays a crucial role, driven by advancements in sensor technology, data analytics, and integration with other diabetes management tools. The regulatory framework, primarily governed by the Medicines and Healthcare products Regulatory Agency (MHRA), significantly influences market access and product approvals. Product substitutes, such as traditional self-monitoring of blood glucose (SMBG), still compete, although CGM's superior convenience and data insights are increasingly driving market shift. End-user trends show a growing preference for minimally invasive, user-friendly devices with advanced features such as remote monitoring and personalized data analysis. The market has witnessed several M&A activities in recent years, with deal values ranging from xx Million to xx Million, primarily driven by the consolidation of market share and the acquisition of promising technologies. Abbott Diabetes Care currently holds an estimated xx% market share, followed by Dexcom Inc with xx%, Medtronic PLC with xx%, and Ascensia Diabetes Care with xx%. The remaining xx% is attributed to “Other Company Share Analyse”, encompassing smaller players and emerging entities.

United Kingdom Continuous Glucose Monitoring Market Industry Trends & Insights

The UK CGM market is experiencing robust growth, projected to achieve a Compound Annual Growth Rate (CAGR) of xx% during the forecast period (2025-2033). This growth is fueled by several factors, including the rising prevalence of diabetes, increasing awareness of CGM benefits among patients and healthcare professionals, technological advancements leading to smaller, more accurate, and user-friendly devices, and supportive government initiatives aimed at improving diabetes management. The market penetration of CGM is currently estimated at xx%, and is expected to rise significantly due to reimbursement policies and growing patient preference for continuous monitoring over intermittent blood glucose testing. Technological disruptions, particularly in areas such as sensor technology, data analytics, and AI-driven insights, are reshaping the competitive landscape and driving innovation. Consumer preferences are increasingly leaning towards smaller, less invasive devices with improved accuracy and better integration with smartphones and other health management apps. The competitive dynamics are characterized by intense innovation, strategic partnerships, and a focus on improving product features and user experience.

Dominant Markets & Segments in United Kingdom Continuous Glucose Monitoring Market

• Dominant Segment: The Sensors segment currently dominates the UK CGM market, accounting for xx Million in revenue in 2025. This dominance is attributed to the continuous need for sensor replacements for ongoing monitoring. The Durables segment is also growing significantly, driven by the increasing demand for CGM devices with longer lifespan and improved usability.

• Key Drivers of Segment Dominance:

  • Technological Advancements: Continuous innovation in sensor technology, including improvements in accuracy, lifespan, and ease of use, is a key driver.
  • Increased Adoption: Rising awareness among healthcare professionals and patients about the benefits of continuous glucose monitoring, driving higher adoption rates.
  • Reimbursement Policies: Favorable reimbursement policies from the National Health Service (NHS) help increase patient access and market expansion.
  • Growing Diabetes Prevalence: The UK has a significant and growing population with diabetes, fueling demand for CGM.

United Kingdom Continuous Glucose Monitoring Market Product Innovations

Recent years have witnessed significant advancements in CGM technology, leading to the development of smaller, more accurate, and user-friendly devices. The introduction of systems like Dexcom G7, with its fast sensor warmup and elimination of finger-stick calibration, highlights the trend towards improved convenience and patient experience. Abbott's FreeStyle Libre 2, with its demonstrated efficacy in improving HbA1c levels and quality of life, further underscores the focus on clinically proven benefits. These innovations are enhancing market acceptance and driving increased adoption. Competition is increasingly focused on differentiating through improved accuracy, longer sensor lifespan, integration with smart devices, and sophisticated data analytics capabilities.

Report Segmentation & Scope

The report segments the UK CGM market based on components: Sensors and Durables.

Sensors: This segment encompasses the disposable sensors used for continuous glucose monitoring. Growth projections indicate a CAGR of xx% during the forecast period, primarily driven by technological advancements leading to more accurate, comfortable and longer-lasting sensors.

Durables: This segment includes the reusable components of CGM systems, such as transmitters and receivers. This segment is also experiencing significant growth due to the increased demand for CGM devices. Market size projections show a significant contribution in the overall market, projected to reach xx Million by 2033. The segment's competitive dynamics reflect a strong focus on device integration and data management capabilities.

Key Drivers of United Kingdom Continuous Glucose Monitoring Market Growth

Several factors contribute to the growth of the UK CGM market. Firstly, the increasing prevalence of diabetes is a major driver. Secondly, technological advancements, such as smaller, more accurate, and user-friendly devices, are making CGM more accessible and appealing. Thirdly, favourable reimbursement policies by the NHS are increasing affordability and accessibility. Lastly, growing awareness and patient preference for continuous monitoring, supported by clinical evidence demonstrating improved glycemic control and quality of life, are significantly pushing market growth.

Challenges in the United Kingdom Continuous Glucose Monitoring Market Sector

The UK CGM market faces challenges such as high device costs, which can pose a barrier for some patients. The reimbursement landscape, while improving, is not yet universally comprehensive. Competition from established players and emerging technologies necessitates continuous innovation to maintain market share. Furthermore, supply chain disruptions can impact product availability and pricing. These factors can collectively affect market expansion, despite the strong growth drivers.

Leading Players in the United Kingdom Continuous Glucose Monitoring Market Market

• Abbott Diabetes Care
• GlySens
• Dexcom Inc
• Eversense
• Medtronic PLC
• Other Company Share Analyse
• Ascensia Diabetes Care

Key Developments in United Kingdom Continuous Glucose Monitoring Market Sector

• October 2022: Abbott announced positive clinical trial results for FreeStyle Libre 2, demonstrating significant HbA1c reduction and improved quality of life for Type-1 diabetes patients. This significantly boosted market confidence and adoption.

• April 2022: Dexcom launched the G7 CGM system in the UK, characterized by faster sensor warmup and ease of use. This launch strengthened Dexcom's market position and broadened CGM accessibility.

Strategic United Kingdom Continuous Glucose Monitoring Market Market Outlook

The UK CGM market is poised for continued strong growth, driven by technological innovation, increasing diabetes prevalence, and favorable regulatory support. Strategic opportunities exist for companies focused on developing innovative, user-friendly devices, improving data analytics and integration with other healthcare platforms, and exploring partnerships with healthcare providers to enhance patient access and outcomes. Expanding reimbursement coverage and educating patients and healthcare professionals about the clinical and economic benefits of CGM will further accelerate market expansion.

United Kingdom Continuous Glucose Monitoring Market Segmentation

• 1. Component
  • 1.1. Sensors
  • 1.2. Durables

United Kingdom Continuous Glucose Monitoring Market Segmentation By Geography

• 1. United Kingdom